Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

NCT01605708 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Pruritus
Atopic Dermatitis

Interventions

DRUG: REGN846

Sponsor

Regeneron Pharmaceuticals